현재 위치：홈 > 뉴스현황 > Press Events > Simple Solution Impr...
저자： 업로드：2015-10-30 조회수：
For decades, immunologists have been on a frenetic quest to find the holy-grail for influenza vaccines—a cross-protective mixture that would allow the immune system to react to a variety of flu strains after a single inoculation. Now, researchers at the University of Melbourne may have found a fairly simple workaround that boosts the effectiveness and cross-protective capabilities of the influenza A vaccine through the addition a simple detergent-like adjuvant compound.
"Influenza infections cause 250,000-500,000 deaths every year. Our best protection comes from the seasonal flu vaccine, which induces antibodies that neutralize the virus," explained lead author Brendon Chua, Ph.D., research fellow at the University of Melbourne. "The holy grail would be to develop a vaccine that cross-protects against different strains, which would be beneficial for the whole community, even if the prediction of circulating strains is wrong."
The findings from this study were published recently in mBio through an article entitled “Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.”
The investigators believed that the addition of the proper adjuvant along with the flu vaccine would stimulate other types of antibody-independent immune responses, resulting in a much improved and cross-protective vaccine.
"We had an adjuvant that worked well to stimulate both innate and adaptive immunity," noted Dr. Chua. "Harnessing both types of immunity would provide protection in that period during an outbreak when no [new] vaccine is available."
Innate immunity is the body’s first line of defense against that quickly attacks foreign antigens in a nonspecific manner. Conversely, the adaptive immune response is the body’s long-term response, which typically generates immune memory specific to the antigen it is trying to attack.
The adjuvant in this study called R4Pam2Cys, is a synthetic lipopeptide—a string of fat molecules connected by a small protein chain that mimics a natural component found on the outer membrane of a pathogenic microorganism. Human immune cells recognize this component as a danger signal.
"This danger signal is the key to the front door of innate immunity," stated senior author David Jackson, Ph.D. professor and vaccine expert at the University of Melbourne. "It initiates the nonspecific innate response that says, 'Get the SWAT squad out here!' "
The Melbourne team added the adjuvant to an
inactivated influenza A vaccine, inocu
